GALT (Galectin Therapeutics) ROCE %: -122.60% (As of Mar. 2026)


GALT Galectin Therapeutics Inc GALT
16 GF Score
Price $3.82
! 5 Warning Signs
View Full Analysis

What is Galectin Therapeutics ROCE %?

Galectin Therapeutics GALT +21.63% 16 ROCE % is -122.60% as of Mar. 2026. GuruFocus rates GALT with a GF Score™ of 16/100. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Galectin Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -122.60%.

Galectin Therapeutics  (NAS:GALT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Galectin Therapeutics ROCE % Related Terms

Galectin Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Galectin Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galectin Therapeutics ROCE % Chart

Galectin Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -105.41 -183.81 -368.07 0.00 0.00

Galectin Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -122.60
GALT
16GF Score
Galectin Therapeutics Inc GALT
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galectin Therapeutics ROCE % Calculation

Galectin Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-23.507/( ( (17.495 - 35.409) + (19.532 - 8.03) )/ 2 )
=-23.507/( (-17.914+11.502)/ 2 )
=-23.507/-3.206
=733.22 %

Galectin Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-12.232/( ( (19.532 - 8.03) + (15.759 - 7.307) )/ 2 )
=-12.232/( ( 11.502 + 8.452 )/ 2 )
=-12.232/9.977
=-122.60 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -122.60% mean?
Galectin Therapeutics (GALT) has a ROCE % of -122.60% as of Mar. 2026.
Is Galectin Therapeutics' ROCE % too high?
Galectin Therapeutics' current ROCE % is -122.60%. Overall, Galectin Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Galectin Therapeutics' ROCE % compare to PRQR and HRTX?
Galectin Therapeutics' ROCE % of -122.60% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Galectin Therapeutics's current ROCE % is -122.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galectin Therapeutics stock overvalued right now?
Galectin Therapeutics (GALT) has a current ROCE % of -122.60%. The current ROCE % is -122.60%. Galectin Therapeutics' overall GF Score™ is 16/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Galectin Therapeutics (GALT), the current ROCE % is -122.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galectin Therapeutics Business Description

Other Exchanges PHPN:Germany
Address 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
16GF Score

Get the complete analysis for GALT

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.82
Price